Articles tagged with Colon Cancer
Researchers developed a novel cell model of aging-related colon cancer risk by combining genetic and epigenetic factors. The model shows that epigenetic changes are essential for cancer initiation, and can be used to assess cancer risk in human lab-grown cells.
A team of University of Wisconsin-Madison scientists has identified four blood-based fingerprints associated with pre-cancerous forms of colon cancer. The findings may lead to a minimally-invasive blood test to increase screening rates and reduce overtreatment.
Researchers at Oregon State University discovered that two hop-derived compounds inhibit liver and colon cancer cell growth effectively similar to xanthohumol. These non-estrogenic derivatives offer promising alternatives for future preclinical studies.
Starting colorectal cancer screening at age 45 rather than 50 would decrease U.S. cancer deaths by as much as 11,100 over five years and cases by up to 29,400. Screening a greater number of older adults would avert nearly three times as many diagnoses and deaths at a lower cost.
A study by Weill Cornell Medicine found that consuming high-fructose corn syrup causes mice with colon cancer to develop larger tumors. The researchers discovered a molecular mechanism by which the sweetener fuels tumor growth and suggest blocking this effect could lead to new cancer treatments.
Researchers found that early-life microbiota play a crucial role in regulating immune responses and preventing colon cancer in adulthood. The absence of microbiota in early life can lead to enhanced pro-inflammatory gene expression and an accumulation of immune cells that suppress tumor growth.
A study published in EMBO Reports found that the common oral bacterium F. nucleatum accelerates colon cancer growth by inducing the production of protein Annexin A1, which stimulates cancer cell growth. This discovery may help predict aggressive colon cancers and identify new treatment targets.
Research published in The Journal of Physiology suggests that exercise may play a role in inhibiting the growth of colon cancer cells. After high-intensity interval training (HIIT), growth was reduced and inflammation increased, indicating a potential anti-cancer effect. This study highlights the importance of regular physical activity...
Researchers at UMass Amherst have discovered a novel therapeutic target, CYP monooxygenase pathway, that could prevent or treat colon cancer. The study found that certain fatty acid metabolites, such as epoxyoctadecenoic acids (EpOMEs), increase inflammation and tumor growth in the colon.
The study found a substantial increase of 230% in colon cancer screenings among Medicaid patients post-ACA expansion. Additionally, data showed a 9.3% rise in early-stage colon cancer diagnosis and a 27% decrease in risk of death.
Researchers at Penn State College of Medicine identified 10 synthetic cannabinoid compounds that effectively inhibited the growth of seven types of human colon cancer cells. These compounds work through alternative mechanisms, not relying on traditional marijuana receptors, and hold promise for developing drugs to treat cancer.
A study published in Cell Reports reveals a critical connection between chronic inflammation and the development of colon cancer. Researchers found that persistent inflammation leads to increased levels of myeloid-derived suppressor cells and interleukin-10, which ultimately silence tumor suppressors and contribute to cancer growth.
Colorectal cancer mortality rates are projected to decrease in most countries, but increase in Europe, North America, and Oceania. The number of deaths is expected to rise globally by 60.0% and 71.5% until 2035.
Researchers found that it took a year or more from first spotting a symptom to beginning treatment for 10% of patients in England, Northern Ireland, and Wales. The time to diagnosis varied significantly across countries, with Denmark performing the best.
A systematic review and meta-analysis found that racial differences in colorectal cancer incidence are not due to biological factors. The study suggests that screening should begin at age 50 regardless of race, with consideration for individual risk factors and preferences. Improved access to screening is crucial to reducing disparitie...
Researchers report a 100% major pathological response rate in early-stage colon cancers with mismatch repair deficiencies treated with nivolumab and ipilimumab. The regimen was well-tolerated, and patients underwent radical resection without delays.
A new study found that inflammatory proteins in the colon increase incrementally with weight in humans, leading to pro-cancerous changes. The study also suggests that NSAIDs may lower the levels of these pro-inflammatory proteins, reducing cancer risk.
Researchers at CWRU School of Medicine are exploring the role of long noncoding RNAs in colon cancer. They have identified potential targets for treatment, including lincDUSP, and found that depleting its levels can slow tumor growth.
A study found that bacteria in the intestines fuel tumor growth in the colon, with chronic inflammation having no effect on cancer development. Microbial therapy is considered a promising approach when more about bacterial flora composition is known.
Scientists from the University of Luxembourg have identified a molecular mechanism responsible for colon cancer cell spread and metastasis. A small molecule cluster, miR-371~373, was found to regulate colon cancer metastasis in aggressive, fast-growing cancer cells. Reactivation of this cluster slowed down metastatic cell growth.
A clinical trial found that using an anti-inflammatory agent during surgery can reduce inflammation and tumor cell growth, potentially improving cancer outcomes. The study tested a solution containing Taurolidine in patients undergoing surgery for colon cancer.
A study from the Francis Crick Institute found that chemicals produced by vegetables like kale and broccoli can prevent colon cancer in mice. The research discovered that these compounds activate a protein called AhR, which helps protect against inflammatory responses to gut bacteria.
Researchers found distinct genetic mutations in appendix cancer that predict survival rates and may impact therapy choices. The study identified specific genes, such as TP53 and GNAS, as biomarkers for high-risk patients.
A large-scale retrospective study has shown that nearly doubling the number of lymph nodes removed during operations for right-sided colon cancers improves the survival rate for these patients. The study found improved outcomes when at least 22 lymph nodes were harvested, with a 20% increase in five-year survival rates.
A Yale University study found that drinking artificially-sweetened beverages is associated with a significantly lower risk of colon cancer recurrence and death. Participants who drank one or more 12-ounce servings of artificially sweetened beverages per day experienced a 46% improvement in risk, compared to those who didn't.
Researchers at Boston University School of Medicine have identified c-Cbl as a potential target protein in colon cancer. High levels of c-Cbl were found to be associated with longer patient survival rates.
A new study by IRB Barcelona researchers reveals that myeloid cells use p38 protein signalling to support inflammation-associated colon cancer. The study suggests IGF-1 as a potential therapeutic target in combination with prior detection of inflammatory infiltration in biopsies.
A research team, led by OHSU physician-scientists, has discovered a drug compound that inhibits cancer cell movement and prevents them from spreading throughout the body. The compound was developed using a multidisciplinary approach, combining chemistry and biology to create a highly effective therapeutic.
The Immunoscore test accurately predicts tumor recurrence risk in patients with colon cancer, enabling intensified treatment after surgery. The test identifies two types of immune cells in the tumor and its invasive margin, providing a reliable estimation of disease progression.
A UCLA-led study found how colon cancer alters its genes to avoid detection by the immune system. The ability of cancer to change its genes, called immunoediting, had never been described in colon cancer before.
Researchers discovered that aspirin blocks TIF-IA, a molecule essential for the nucleolus to function, driving tumour formation and dysfunction. Regular use of aspirin may help pinpoint those most likely to benefit from the treatment.
A new mouse study suggests that the widely used antimicrobial ingredient triclosan may have adverse effects on colonic inflammation and colon cancer. Researchers found that triclosan altered gut microbiota, increased inflammation, and spurred disease development in mice.
Researchers found that triclosan causes colon inflammation and worsens colon cancer in mice, raising concerns about its safety for human consumption. The study suggests that individuals with inflammatory bowel disease or colon cancer may be more vulnerable to the chemical's adverse effects.
Research suggests that being overweight in childhood and having above-average weight gain during puberty increases the risk of developing adult colon cancer in men. However, this risk is not present for boys who do not experience significant weight gain during puberty.
Researchers discovered colon cancers are composed of two different cell types that can replace each other when one is killed. Targeting both cell populations simultaneously showed strong repressive effects on tumor cell proliferation and increased cell death, resulting in slower tumor growth and prolonged survival times.
Researchers discovered that colon cancer cells rely on unusually long RNA strands, called lincRNAs, to evade cell death and promote unregulated growth. Targeting these molecules could lead to effective treatments.
Early-stage colon cancers can be surgically removed but later stages require targeted treatments. Researchers discovered that colon cancers are composed of two different cell types with the ability to replace each other after one is killed.
A study published in the International Journal of Cancer found that regularly eating red meat increases the risk of distal colon cancer in women, with those on a red meat-free diet experiencing lower rates. The research suggests that a diet free from red meat significantly reduces the risk of this type of colon cancer.
A lifestyle consistent with American Cancer Society (ACS) guidelines was associated with a lower risk of death in patients with stage III colon cancer. Patients who followed these guidelines had improved survival rates compared to those who did not.
Two common iron compounds, ferric citrate and ferric EDTA, have been shown to increase the formation of a known biomarker for cancer, amphiregulin. This is the case even at low doses. The study suggests that these iron supplements may be carcinogenic.
Researchers have discovered a new function of the APC protein, which puts the brakes on colon cancer activators. This finding may lead to identification of additional drug targets and improved therapeutic strategies for colon cancer patients.
A new study suggests that a diet free from red meat significantly reduces the risk of distal colon cancer in women living in the UK. The study analyzed data from over 32,000 women and found that those regularly eating red meat had higher rates of distal colon cancer compared to a red meat-free diet.
A global clinical trial collaboration published in the New England Journal of Medicine found that stage III colon cancer patients can cut their chemotherapy treatments in half after surgery, reducing costs and side effects. For low-risk patients with shallow tumors and few affected lymph nodes, a three-month course is shown to be safe ...
Researchers at the Oklahoma Medical Research Foundation have made a groundbreaking discovery about colon cancer, revealing that certain hidden polyps may be responsible for up to 30-40% of cases. The study also found that these polyps are caused by a mutation in the BRAF gene and could potentially be detected through fecal samples.
A new iPad app that educates patients about different options for colon cancer screening and allows them to order their preferred test has been shown to significantly increase screening rates. In a randomized controlled trial, patients who used the app were twice as likely to undergo screening compared to those in the usual care group.
A new iPad app, mPATH-CRC, was developed to improve colon cancer screening rates. The app simplified the process of ordering a screening test, increasing screenings from 15% to 30% among participants. While the app showed promise, it is not intended to replace doctors' care, but rather to augment it and encourage patient participation.
A new study found that people who regularly eat nuts have a significantly lower risk of colon cancer recurrence and mortality. Nuts also improve disease-free survival and overall survival rates by reducing insulin resistance. Regular nut consumption is associated with being leaner, contrary to concerns about high fat content.
Researchers at IRB Barcelona have discovered that immune system-stimulating treatments combined with a TGF-beta inhibitor are effective against colon cancer. They developed a mouse model that mimics advanced human colon cancer, allowing them to examine how cancer cells evade the immune system.
Researchers found that Bacteroides fragilis and Escherichia coli bacteria work together to create a microenvironment that induces chronic inflammation and DNA damage, supporting tumor formation. This discovery could lead to more effective screening and prevention strategies for colon cancer.
Researchers identified an enzyme that is absent in healthy colon tissue but abundant in colon cancer cells. The enzyme, GalNAc-T6, attaches sugar molecules to proteins, affecting cell-cell adhesion and leading to abnormal tissue formation. This discovery may lead to new therapies for colon cancer.
A new UCLA study found that a high-cholesterol diet can accelerate the formation of tumors in the colon by speeding up intestinal stem cell division. The research identified a molecular pathway that could serve as a new target for colon cancer treatment.
A recent study by Texas Tech University Health Sciences Center El Paso aims to identify the most accurate stool test for detecting colorectal cancer. The research consortium will compare four different fecal immunochemical tests (FITs) to determine their effectiveness in detecting blood in the stool, a common early sign of cancer.
Research from MD Anderson Cancer Center finds improved adherence to surgical treatment guidelines, but chemotherapy guideline adherence remains largely unchanged. Informed patient-physician discussions are crucial for better survival outcomes and quality care.
A Kaiser Permanente study found that live phone calls are significantly more effective at reminding patients to complete and return at-home fecal screening tests for colon cancer. Phone calls outperformed other reminder strategies, including text messages and letters, especially among Spanish-speaking patients.
Researchers have identified a new genetic marker, BRF1, associated with up to 1.4% of hereditary colon cancer cases. The finding allows for personalized follow-up programs and potential prevention of early onset cancer in mutation carriers.
Researchers found that pigs fed a high-calorie diet supplemented with purple-fleshed potatoes had lower levels of inflammation-linked protein IL-6, compared to those on a standard diet. This study suggests that whole foods containing macronutrients and phytonutrients may be effective in preventing colon cancer.
A new study reveals that the IGPR-1 protein plays a critical role in colon tumor growth and drug resistance, identifying it as a potential target for treatment. Blocking IGPR-1 with an antibody or shRNA inhibits tumor growth, suggesting significant therapeutic potential.
A recent ESMO 2017 Congress session has ignited debate on the optimal duration of adjuvant chemotherapy for colon cancer, with experts weighing in on the pros and cons of shortening treatment from six to three months. The IDEA study suggests that three months provides a similar benefit but with reduced side effects.
Researchers at VCU Massey Cancer Center have found a potential cure for colon cancer by targeting the gene CtBP with a drug called HIPP, which reduces pre-cancerous polyps by half and increases mouse lifespan. This breakthrough may also extend to other cancers depending on the same mechanism.
The University of Arizona researchers will investigate NHE8's role in gastrointestinal diseases, including IBD and colon cancer. They aim to understand how this protein affects goblet cell function, gut microbiome balance, and epithelial cell proliferation.